2 options
Pfizer Inc. : the Torcetrapib failure and the future of the world's largest drug manufacturer / Yufei Du, Mark Simpson, Devis Katro, James Mitchell, James S. O'Rourke.
- Format:
- Book
- Author/Creator:
- Du, Yufei, author.
- Simpson, Mark, author.
- Katro, Devis, author.
- Mitchell, James, author.
- O'Rourke, James S., IV, 1946- author.
- Series:
- SAGE Knowledge. Cases.
- SAGE Knowledge. Cases
- Language:
- English
- Subjects (All):
- Pfizer Inc.
- Pharmaceutical industry--Public relations.
- Pharmaceutical industry.
- Anticholesteremic agents--Testing.
- Anticholesteremic agents.
- Physical Description:
- 1 online resource : illustrations.
- Place of Publication:
- London : SAGE Publications Ltd, 2017.
- System Details:
- text file
- Summary:
- In December 2006, Pfizer announced the halt of the Torcetrapib clinical trial, a once very promising drug in the fight against coronary artery and heart disease. At the same time, Pfizer announced its initial plans of layoffs and cost reductions would be expedited as a result of the trials. With the loss of patent protections for a series of drugs including Lipitor, the cancellation of Bextra, and the black label warning on Celebrex tablets, how does Pfizer seek continued success while appeasing shareholders?
- Notes:
- Originally published: Du, Y., Simpson, M., Katro, D., Mitchell, J. & ORourke, J. S. (2007). Pfizer Inc.: The Torcetrapib failure and the future of the worlds largest drug manufacturer. 07-01. Notre Dame, IN: The Eugene D. Fanning Center for Business Communication, Mendoza College of Business, University of Notre Dame.
- No ILL or scholarly sharing allowed.
- Description based on XML content.
- ISBN:
- 9781526405708
- OCLC:
- 1017729381
- Access Restriction:
- Restricted for use by site license.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.